RE: Avacta30 Jun 2021 09:14
While Covid is still causing chaos for several companies, biotechnology company Avacta has been making money with its lateral flow tests.
It revealed that its diagnostic tests could detect the Delta variant which is becoming widespread in the UK, and that it outperformed two similar tests available in Europe. It climbed 4.6 per cent, or 8p, to 182p.